Enzalutamide + Docetaxel + Prednisolone + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castration Resistant Prostate Cancer
Conditions
Metastatic Castration Resistant Prostate Cancer
Trial Timeline
Dec 1, 2014 → Mar 15, 2024
NCT ID
NCT02288247About Enzalutamide + Docetaxel + Prednisolone + Placebo
Enzalutamide + Docetaxel + Prednisolone + Placebo is a phase 3 stage product being developed by Astellas Pharma for Metastatic Castration Resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02288247. Target conditions include Metastatic Castration Resistant Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castration Resistant Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02288247 | Phase 3 | Completed |
Competing Products
20 competing products in Metastatic Castration Resistant Prostate Cancer